Search anything
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
Piramal Pharma reported FY26 standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore, alongside director re-appointments and key compliance and office changes.
Piramal Pharma reported FY2026 audited revenues, with higher standalone profit but a consolidated net loss, alongside leadership re-appointments and a new company secretary appointment effective April 29, 2026.
Piramal Pharma reported FY2026 standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore, alongside director re-appointments, a new compliance officer, and an office address change.
Piramal Pharma reported FY2026 standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore, alongside board re-appointments and a new company secretary from April 29, 2026.
Piramal Pharma reported FY2026 standalone revenue ₹4,782.01 crore and consolidated revenue ₹8,869.08 crore, alongside director re-appointments and a new compliance officer from April 29, 2026.
Piramal Pharma reported FY2026 standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore, alongside director re-appointments and a new company secretary from April 29, 2026.
Bagmane Prime Office REIT’s Rs 3,405 crore IPO opens May 5, 2026 with a Rs 95-100 price band, combining a fresh issue and OFS to fund acquisitions.
Kiniksa Pharmaceuticals International shares extended a strong 12-month run as traders reacted to sharp near-term price momentum, upbeat earnings-surprise metrics, and ARCALYST revenue growth expectations.
Blackstone-backed Bagmane Prime Office REIT will open its ₹3,405 crore IPO on May 5, 2026, outlining a fresh issue, OFS mix, portfolio details, and use of proceeds.
Brent’s move above $110 alongside sharp backwardation and steep inventory draws highlights physical supply stress from the West Asia conflict, raising inflation and fiscal risks for India.
A widening Iran-Israel conflict has lifted crude prices and disrupted shipping routes, triggering a rare retail fuel hike by Nayara Energy and renewed inflation concerns for India.
Brent settled above $111 and WTI near $100 as the Strait of Hormuz disruption tightened supply expectations, overshadowing the UAE’s decision to leave OPEC+ from May 1.
Emmvee Photovoltaic Power’s Q3 FY26 filings showed sharp year-on-year growth in revenue, EBITDA and profit, alongside a 9.3 GW order book and capacity expansion plans.
Emmvee Photovoltaic Power is expected to report Q4 FY26 results on April 28, with analysts pencilling 16% revenue growth and higher EBITDA and PAT year-on-year.
Piccadily Agro’s board approved FY26 audited results, a sugar-business demerger into wholly owned PFEL, and a statutory auditor change, all subject to regulatory and shareholder approvals.
Piccadily Agro reported sharp Q3 FY26 growth led by its distillery business, while different result summaries in the shared data show a gap on consolidated profitability.
